Skip to main content
UniHealth

Doctor search

Charalambos Andreadis, MD

Hematology/Oncology · San Francisco

NPI 1205877669

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
12
2 carriers
Offices
4
Since medical school
28 years
Columbia University College of Physicians and Surgeons, 1998

Offices

4 locations · University of California San Francisco · UCSF Medical Group Business Services · Regents of the University of California

Looking this up.

Hospitals listed: John Muir Medical Center - Walnut Creek Campus · UCSF Medical Center. That is not proof they admit you there this week.

Plans that list them

12 plans · 2 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Andreadis’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

12 of 12 plans

Plans whose provider directory lists this clinician
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026
Imperial Courage Plan (HMO)Imperial Health Plan of California, Inc.ListedSep 1, 2026
Imperial Dynamic Plan (HMO)Imperial Health Plan of California, Inc.ListedSep 1, 2026
Imperial Senior Value (HMO C-SNP)Imperial Health Plan of California, Inc.ListedSep 1, 2026

Hospitals they work in

2 hospitals

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • John Muir Medical Center - Walnut Creek CampusWalnut Creek, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of John Muir Health, which runs 3 hospitalsPatients rate it 3 of 5 · 77% would definitely recommend it
    Overall rating: 2 of 5 starsWorse than the national rate — Abdominopelvic accidental puncture or laceration rate: 2.01 (1.17 to 2.85) · 2,206 cases, Jul 2022 – Jun 2024Worse than the national rate — Death rate among surgical inpatients with serious treatable complications: 222.42 (177.82 to 267.02) · 120 cases, Jul 2022 – Jun 2024Worse than the national rate — Pressure ulcer rate: 1.4 (0.91 to 1.9) · 9,764 cases, Jul 2022 – Jun 2024Worse than the national rate — SSI - Colon Surgery: 2.734, Oct 2024 – Sep 2025Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.536, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.341, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.455, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.245, Oct 2024 – Sep 2025
  • UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend it
    Overall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for John Muir Medical Center - Walnut Creek Campus

Behind the star rating — Deaths: 3 better, 2 the same, 2 worse of 7 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 3 better, 5 the same, 2 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at John Muir Medical Center - Walnut Creek Campus
Abdominopelvic accidental puncture or laceration rateComplications and deaths2.01 (1.17 to 2.85) · 2,206 casesWorseJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths222.42 (177.82 to 267.02) · 120 casesWorseJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths1.4 (0.91 to 1.9) · 9,764 casesWorseJul 2022 – Jun 2024
SSI - Colon SurgeryInfections2.734WorseOct 2024 – Sep 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.536BetterOct 2024 – Sep 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.341BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.455BetterOct 2024 – Sep 2025
MRSA BacteremiaInfections0.245BetterOct 2024 – Sep 2025
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths1.14 (0.87 to 1.4)No differentJul 2022 – Jun 2024
Death rate for COPD patientsComplications and deaths6.4 · 131 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths10 · 148 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths9.8 · 695 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths12.5 · 827 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths14.1 · 509 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths3.4 · 4,483 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.35 (0.18 to 0.53) · 11,630 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.22 (0.05 to 0.39) · 11,793 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths3.33 (1.69 to 4.96) · 3,268 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.37 (0 to 2.94) · 1,631 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.76 (1.43 to 4.09) · 3,066 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths6.12 (0.22 to 12.02) · 1,580 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths4.43 (1.21 to 7.64) · 1,594 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.82 (0.4 to 3.24) · 685 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.9 · 615 casesNoneApr 2023 – Mar 2025
SSI - Abdominal HysterectomyInfections1.88No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits14.7 · 93 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits19.9 · 729 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits-30.1 · 91 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-13 · 736 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits34.8 · 842 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.7 · 818 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.3 (3.3 to 8.4) · 28 casesNo differentJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits10.8 (7.2 to 15.5) · 28 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits4.9 · 584 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits20.4 · 139 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits13.2 (9.9 to 17.9) · 222 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits1.1 (0.8 to 1.5) · 321 casesNo differentJan 2024 – Dec 2024

What patients said (758 patients answered, 24% of those asked)

Patient survey stars by topic at John Muir Medical Center - Walnut Creek Campus
Cleanliness3
Nurse communication3
Doctor communication3
Communication about medicines2
Discharge information4
Overall hospital rating3
Quietness3
Recommend hospital4
Share of patients giving the best answer at John Muir Medical Center - Walnut Creek Campus
Room was "always" clean65%
Nurses "always" communicated well75%
Doctors "always" communicated well76%
Staff "always" explained55%
Yes, staff "did" give patients this information87%
Yes, staff "did" give patients information about help after discharge87%
Doctors "always" explained things so they could understand70%
Doctors "always" listened carefully75%
Doctors "always" treated them with courtesy and respect82%
Patients who gave a rating of "9" or "10" (high)69%
Staff "always" explained new medications68%
Nurses "always" explained things so they could understand71%
Nurses "always" listened carefully72%
Nurses "always" treated them with courtesy and respect83%
"Always" quiet at night53%
"YES", patients would definitely recommend the hospital77%
Staff "always" explained possible side effects42%
Yes, staff "did" give patients information about possible symptoms87%
See every measure and the patient survey for UCSF Medical Center

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at UCSF Medical Center
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths4.9 (3.79 to 6.02) · 7,590 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits12.8 (11.3 to 14.4) · 2,019 casesWorseJan 2024 – Dec 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths139.4 (110.22 to 168.58) · 452 casesBetterJul 2022 – Jun 2024
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.622BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.626BetterOct 2024 – Sep 2025
MRSA BacteremiaInfections0.491BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.8 (0.7 to 1) · 2,336 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.24 (0.58 to 1.9) · 4,689 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths1.05 (0.89 to 1.2)No differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.9 · 89 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths7.5 · 85 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths10.1 · 132 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.6 · 454 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 618 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths9.6 · 380 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.7 · 5,000 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.22 (0.06 to 0.38) · 15,965 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.2 (0.05 to 0.35) · 17,859 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.85 (0 to 1.83) · 4,184 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2 (1.1 to 2.9) · 6,516 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths7.35 (4.49 to 10.21) · 3,989 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5 (3.22 to 6.77) · 4,087 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.95 (0.74 to 3.15) · 2,034 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.95 (0.63 to 1.28) · 15,431 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths4 · 399 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.899No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.689No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections1.224No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16 · 156 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20 · 564 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits60.3 · 160 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-9.7 · 550 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits44.1 · 660 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.8 · 667 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.7 (4.8 to 6.7) · 2,019 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits6 · 421 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits10.5 · 53 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits20 · 107 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits13.9 (11.3 to 17.1) · 3,247 casesNo differentJan 2022 – Dec 2024

What patients said (3,181 patients answered, 25% of those asked)

Patient survey stars by topic at UCSF Medical Center
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at UCSF Medical Center
Room was "always" clean71%
Nurses "always" communicated well80%
Doctors "always" communicated well80%
Staff "always" explained61%
Yes, staff "did" give patients this information88%
Yes, staff "did" give patients information about help after discharge87%
Doctors "always" explained things so they could understand74%
Doctors "always" listened carefully78%
Doctors "always" treated them with courtesy and respect86%
Patients who gave a rating of "9" or "10" (high)76%
Staff "always" explained new medications75%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully78%
Nurses "always" treated them with courtesy and respect86%
"Always" quiet at night50%
"YES", patients would definitely recommend the hospital81%
Staff "always" explained possible side effects46%
Yes, staff "did" give patients information about possible symptoms90%

Original Medicare doctor bills

$77,466

Medicare paid this office $77,466 for 232 people. Most of that is long return visits and Botox.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Long return visit (40+ min)147$38,729$118
Return visit (30+ min)88$8,607$73
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's191$5,411$14
New patient visit (60+ min)26$3,692$142
Biopsy and aspiration of bone marrow sample for diagnosis16$1,136$67
See all 6 services
Every Original Medicare service billed
Long return visit (40+ min)147$38,729$118
Return visit (30+ min)88$8,607$73
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's191$5,411$14
New patient visit (60+ min)26$3,692$142
Biopsy and aspiration of bone marrow sample for diagnosis16$1,136$67
Insertion of needle into vein for collection of blood sample15$545$9

Procedures year by year

Procedures billed to Original Medicare by year
Procedure201920202021202220232024
Biopsy and aspiration of bone marrow sample for diagnosis––14161117

Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.

Who their Medicare patients are

232 Original Medicare patients in 2024. Average age 73 · Under 65 10% · 85 and older 6% · Women 45% · Also on Medicaid 17% · Health risk score 2.38. Above the middle of the specialty; the typical hematology-oncology clinician is at 2.04.

Conditions among them: High blood pressure 60% · Chronic kidney disease 25% · Coronary heart disease 24% · Depression 23% · Diabetes 22% · Atrial fibrillation 22% · Cancer 20% · Heart failure 18% · COPD 12% · Stroke 7% · Dementia 6%.

The office billed $675,475, Medicare allowed $105,116 and paid $77,466; for 3,355 services of 29 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
20242323,355732.38$675,475$77,466
20232491,791722.52$731,867$88,669
2022249659712.39$474,132$62,785
2021219996722.76$522,753$61,326
2020163494722.84$425,667$37,210
2019174462713.00$440,418$43,382
2018180496702.76$502,047$42,460
2017198583693.07$558,816$46,868
2016182794672.99$708,265$66,160
2015169702672.97$662,776$58,261
2014166697652.68$794,152$55,979
2013137699632.58$726,995$51,817

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 6 services

Original Medicare services billed in 2023
Long return visit (40+ min)138$36,937$121
Return visit (30+ min)95$8,353$67
New patient visit (60+ min)28$4,542$162
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes17$4,507$107
Biopsy and aspiration of bone marrow sample for diagnosis11$750$68
Insertion of needle into vein for collection of blood sample22$487$8

2022: 6 services

Original Medicare services billed in 2022
Long return visit (40+ min)142$36,786$123
Return visit (30+ min)81$7,825$74
New patient visit (60+ min)48$7,514$157
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes17$4,462$91
Biopsy and aspiration of bone marrow sample for diagnosis16$920$57
Insertion of needle into vein for collection of blood sample17$106$3

2021: 5 services

Original Medicare services billed in 2021
Long return visit (40+ min)119$32,301$121
New patient visit (60+ min)48$7,734$161
Return visit (30+ min)75$7,114$76
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes21$5,121$91
Biopsy and aspiration of bone marrow sample for diagnosis14$984$70

2020: 3 services

Original Medicare services billed in 2020
Long return visit (40+ min)128$27,532$92
New patient visit (60+ min)22$3,354$152
Return visit (30+ min)36$2,378$61

2019: 4 services

Original Medicare services billed in 2019
Long return visit (40+ min)133$31,081$91
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes21$4,662$93
New patient visit (60+ min)31$4,652$150
Return visit (30+ min)12$924$71

2018: 4 services

Original Medicare services billed in 2018
Long return visit (40+ min)96$16,271$96
Return visit (30+ min)91$9,306$59
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes32$8,801$93
New patient visit (60+ min)17$2,533$149

2017: 6 services

Original Medicare services billed in 2017
Long return visit (40+ min)60$12,336$90
Return visit (30+ min)95$12,055$61
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes29$9,142$92
New patient visit (60+ min)25$3,416$137
Biopsy of bone marrow28$2,012$67
Short return visit (20+ min)14$804$40

2016: 8 services

Original Medicare services billed in 2016
Long return visit (40+ min)69$23,519$94
Return visit (30+ min)93$13,460$66
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes31$13,281$92
New patient visit (60+ min)16$2,282$143
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes13$1,921$64
Biopsy of bone marrow18$1,560$68
Short return visit (20+ min)19$1,192$43
Hospital discharge day management, 30 minutes or less15$984$66

2015: 8 services

Original Medicare services billed in 2015
Long return visit (40+ min)62$26,649$95
Return visit (30+ min)70$11,055$66
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes26$7,457$92
New patient visit (60+ min)14$2,097$150
Short return visit (20+ min)27$1,834$44
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes15$1,499$65
New patient visit (45+ min)13$1,395$107
Biopsy of bone marrow17$1,256$66

2014: 7 services

Original Medicare services billed in 2014
Long return visit (40+ min)61$18,968$97
Return visit (30+ min)77$16,890$63
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes25$7,054$93
New patient visit (60+ min)15$2,254$150
Initial hospital care with moderate level of medical decision making at least 75 minutes11$1,987$181
Biopsy of bone marrow19$1,321$70
Short return visit (20+ min)21$1,082$43

2013: 7 services

Original Medicare services billed in 2013
Return visit (30+ min)75$19,253$64
Long return visit (40+ min)41$11,134$91
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes34$8,306$90
Mechanical separation of white blood cells and platelets from blood11$3,614$93
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes17$2,559$58
Short return visit (20+ min)21$1,138$41
Hospital discharge day management, 30 minutes or less12$784$60

Medicaid work

$16,761 in 2024

Medicaid paid $16,761 for 120 billed services this clinician did in 2024, up to 20 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2024
Long return visit (40+ min)120$16,761
Medicaid work by year
2024120120$16,761
2023123118$16,942
2022187321$18,971
202150314$4,198
202037122$2,524
2019429432$21,871
2018283722$4,389
See the largest Medicaid services in earlier years

2023

Largest Medicaid services in 2023
Long return visit (40+ min)123$16,942

2022

Largest Medicaid services in 2022
Long return visit (40+ min)159$18,012
COMPREHENSIVE METABOLIC PANEL14$677
Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count14$282

2021

Largest Medicaid services in 2021
COMPREHENSIVE METABOLIC PANEL17$1,773
Long return visit (40+ min)15$1,754
Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count18$671

2020

Largest Medicaid services in 2020
Long return visit (40+ min)37$2,524

2019

Largest Medicaid services in 2019
Long return visit (40+ min)188$16,700
COMPREHENSIVE METABOLIC PANEL60$2,391
Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count127$2,152
Lactate dehydrogenase (LD), (LDH)54$628

2018

Largest Medicaid services in 2018
Long return visit (40+ min)33$2,598
Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count121$670
Return visit (30+ min)12$533
COMPREHENSIVE METABOLIC PANEL63$429
Hospital outpatient clinic visit for assessment and management of a patient20$97
COLLECTION VENOUS BLOOD VENIPUNCTURE17$61
Lactate dehydrogenase (LD), (LDH)17$0

Drugs they prescribed that Part D paid

$3,894,959

Pharmacies billed $3,894,959 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

463 generic and fewer than 11 brand-name prescriptions · $3,894,959 in drug cost · 53 antibiotic prescriptions to 18 people.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Calquence54$749,431$13,878
Revlimid37$692,836$18,725
Venclexta52$610,710$11,744
Brukinsa35$506,681$14,477
Imbruvica26$445,177$17,122
See all 17 drugs
Every Part D drug this clinician prescribed
CalquenceNone54$749,431$13,878
RevlimidNone37$692,836$18,725
VenclextaNone52$610,710$11,744
BrukinsaNone35$506,681$14,477
ImbruvicaNone26$445,177$17,122
JaypircaNone19$400,936$21,102
LenalidomideNone18$253,983$14,110
Gamunex-CImmune globulin12$35,767$2,981
EntecavirNone29$6,548$226
AtovaquoneNone18$4,450$247
AcyclovirNone125$2,543$20
ValacyclovirNone15$1,305$87
OndansetronNone30$351$12
Sulfamethoxazole-TrimethoprimNone30$133$4
PrednisoneNone33$124$4
LevofloxacinNone14$114$8
LorazepamNone18$64$4

Year by year

Part D prescribing by year
202473396NoneNone$3,894,959
202358094NoneNone$2,379,219
2022579101NoneNone$1,514,189
202162378None26%$1,617,375
2020685782% (11)33%$2,461,754
2019616643% (19)27%$1,591,005
201859780None32%$1,865,295
20177431163% (21)None$1,536,319
20168171062% (18)21%$1,200,901
201573971NoneNone$897,513
2014670704% (28)21%$666,867
2013657572% (15)14%$380,718

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 16 drugs

Part D drugs prescribed in 2023
Calquence47$743,722$15,824
Revlimid20$387,270$19,363
Imbruvica26$355,137$13,659
Venclexta18$253,791$14,100
Entecavir20$19,335$967
Eliquis13$9,625$740
Acyclovir110$2,899$26
Valacyclovir14$1,540$110
Gabapentin11$343$31
Levothyroxine12$276$23
Levofloxacin15$224$15
Ondansetron22$169$8
Prednisone22$112$5
Sulfamethoxazole-Trimethoprim35$103$3
Allopurinol12$55$5
Lorazepam11$43$4

2022: 18 drugs

Part D drugs prescribed in 2022
RevlimidNone17$327,850$19,285
ImbruvicaNone26$318,687$12,257
CalquenceNone12$170,195$14,183
BrukinsaNone13$163,729$12,595
Gamunex-CImmune globulin12$36,342$3,028
EliquisNone25$14,307$572
EntecavirNone27$13,241$490
AtovaquoneNone13$11,238$864
AcyclovirNone98$2,164$22
ValacyclovirNone13$1,309$101
AzithromycinNone14$360$26
OndansetronNone25$311$12
PrednisoneNone29$223$8
GabapentinNone15$208$14
Prochlorperazine MaleateNone18$153$9
Sulfamethoxazole-TrimethoprimNone27$92$3
LorazepamNone22$74$3
AllopurinolNone13$59$5

2021: 17 drugs

Part D drugs prescribed in 2021
RevlimidNone39$677,808$17,380
ImbruvicaNone36$414,138$11,504
CalquenceNone13$187,372$14,413
Gamunex-CImmune globulin24$71,684$2,987
EntecavirNone50$23,665$473
EliquisNone12$6,327$527
AcyclovirNone106$2,646$25
ValacyclovirNone16$978$61
FluconazoleNone14$659$47
OndansetronNone29$567$20
AzithromycinNone19$333$18
GabapentinNone26$276$11
PrednisoneNone28$263$9
LevofloxacinNone17$163$10
Sulfamethoxazole-TrimethoprimNone27$161$6
Prochlorperazine MaleateNone13$125$10
AllopurinolNone13$72$6

2020: 18 drugs

Part D drugs prescribed in 2020
ImbruvicaNone85$1,106,549$13,018
RevlimidNone50$848,433$16,969
CalquenceNone11$157,861$14,351
JakafiNone11$148,095$13,463
PosaconazoleNone14$45,814$3,272
Gamunex-CImmune globulin12$33,145$2,762
EntecavirNone51$18,659$366
EliquisNone18$9,474$526
UrsodiolNone11$4,974$452
FluconazoleNone31$3,702$119
AcyclovirNone89$2,226$25
DexamethasoneNone18$1,779$99
ValacyclovirNone11$951$86
AzithromycinNone21$294$14
GabapentinNone17$266$16
LevofloxacinNone15$252$17
PrednisoneNone17$82$5
Sulfamethoxazole-TrimethoprimNone11$61$6

2019: 16 drugs

Part D drugs prescribed in 2019
Imbruvica65$755,892$11,629
Calquence14$192,653$13,761
Revlimid12$188,752$15,729
Entecavir41$19,236$469
Eliquis20$9,107$455
Fluconazole33$3,999$121
Acyclovir66$1,434$22
Azithromycin19$748$39
Dexamethasone14$315$22
Gabapentin15$245$16
Ondansetron15$211$14
Sulfamethoxazole-Trimethoprim40$172$4
Prednisone20$160$8
Prochlorperazine Maleate14$140$10
Lorazepam21$111$5
Allopurinol18$106$6

2018: 13 drugs

Part D drugs prescribed in 2018
Imbruvica84$941,159$11,204
Revlimid29$441,766$15,233
Venclexta17$192,222$11,307
Noxafil14$82,890$5,921
Entecavir30$23,960$799
Enoxaparin13$2,179$168
Acyclovir79$1,283$16
Azithromycin20$812$41
Valacyclovir13$374$29
Prednisone32$245$8
Gabapentin11$183$17
Sulfamethoxazole-Trimethoprim36$91$3
Lorazepam11$63$6

2017: 16 drugs

Part D drugs prescribed in 2017
Imbruvica79$878,583$11,121
Revlimid15$229,090$15,273
Venclexta13$132,869$10,221
Entecavir37$30,307$819
Xarelto18$7,301$406
Eliquis11$5,195$472
Acyclovir93$1,174$13
Hydroxyurea29$756$26
Fluconazole14$340$24
Ondansetron14$266$19
Prednisone37$236$6
Omeprazole12$218$18
Gabapentin13$155$12
Sulfamethoxazole-Trimethoprim36$110$3
Lorazepam28$77$3
Levofloxacin16$74$5

2016: 20 drugs

Part D drugs prescribed in 2016
Imbruvica81$832,761$10,281
Revlimid13$150,878$11,606
Noxafil23$120,595$5,243
Entecavir42$31,576$752
Acyclovir132$1,674$13
Methotrexate16$1,284$80
Tacrolimus16$1,144$72
Mercaptopurine17$1,011$59
Fluconazole16$919$57
Azithromycin28$609$22
Dapsone12$551$46
Gabapentin30$434$14
Levofloxacin18$286$16
Ondansetron17$278$16
Prednisone29$258$9
Lansoprazole12$186$15
Metoprolol27$170$6
Sulfamethoxazole-Trimethoprim20$112$6
Atorvastatin11$101$9
Lorazepam26$90$3

2015: 21 drugs

Part D drugs prescribed in 2015
Imbruvica51$475,642$9,326
Revlimid17$134,094$7,888
Enoxaparin25$21,489$860
Entecavir24$20,448$852
Ursodiol12$3,434$286
Fluconazole33$3,172$96
Qvar11$2,057$187
Acyclovir97$1,309$13
Mercaptopurine12$1,069$89
Omeprazole27$496$18
Dapsone14$479$34
Azithromycin23$473$21
Ondansetron15$432$29
Prednisone34$354$10
Atorvastatin36$236$7
Gabapentin15$235$16
Lorazepam28$195$7
Montelukast16$191$12
Levofloxacin12$177$15
Sulfamethoxazole-Trimethoprim27$133$5
Glipizide12$45$4

2014: 20 drugs

Part D drugs prescribed in 2014
Imbruvica27$257,591$9,540
Revlimid25$189,776$7,591
Enoxaparin14$32,817$2,344
Baraclude18$21,506$1,195
Ursodiol13$3,820$294
Fluconazole19$2,212$116
Acyclovir78$1,220$16
Levofloxacin25$960$38
Azithromycin23$832$36
Dapsone13$697$54
Omeprazole30$691$23
Gabapentin26$424$16
Atorvastatin33$318$10
Ondansetron13$280$22
Hydrocodone-Acetaminophen20$269$13
Sulfamethoxazole-Trimethoprim19$229$12
Zolpidem18$178$10
Prednisone12$130$11
Lorazepam20$81$4
Allopurinol13$59$5

2013: 15 drugs

Part D drugs prescribed in 2013
Revlimid18$182,505$10,139
Enoxaparin17$38,745$2,279
Baraclude15$15,501$1,033
Acyclovir98$1,861$19
Fluconazole25$1,467$59
Valacyclovir14$1,026$73
Omeprazole37$818$22
Gabapentin37$645$17
Sulfamethoxazole-Trimethoprim37$367$10
Atorvastatin15$288$19
Levofloxacin18$272$15
Lorazepam31$143$5
Allopurinol20$96$5
Amlodipine Besylate14$93$7
Zolpidem11$71$6

Money from drug and device companies

$18,943 in 2025

Industry payments by year
2025721$17,201$18,943
2024419$14,555$15,973
2023712$3,690$4,423
2022716$10,686$11,521
202157$4,425$4,523
202023$10,695$10,695
2019428$13,640$19,640

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
E.R. Squibb & Sons L.L.C.None$11,599
4 payments
  • Meals · 2025-08-29 · $48
  • Travel · 2025-08-29 · $91
  • Consulting · 2025-08-18 · $9,073
  • Consulting · 2025-03-05 · $2,388
Genmab U.S.Epkinly$3,651
4 payments
  • Meals for Epkinly · 2025-12-06 · $122
  • Meals for Epkinly · 2025-11-08 · $41
  • Meals for Epkinly · 2025-11-08 · $102
  • Consulting for Epkinly · 2025-11-08 · $3,386
IncyteNone$2,055
1 payment
  • Consulting · 2025-05-29 · $2,055
CelgeneNone$927
6 payments
  • Meals · 2025-08-06 · $65
  • Meals · 2025-08-06 · $28
  • Meals · 2025-08-06 · $30
  • Meals · 2025-08-06 · $50
  • Travel · 2025-08-06 · $462
  • Travel · 2025-08-05 · $293
AbbvieEpkinly$578
4 payments
  • Meals for Epkinly · 2025-12-05 · $149
  • Meals for Epkinly · 2025-08-27 · $108
  • Consulting for Epkinly · 2025-07-14 · $300
  • Meals for Imbruvica · 2025-01-30 · $21
GenentechColumvi$102
1 payment
  • Meals for Columvi · 2025-06-20 · $102
See all 21 published payments
Every published payment
Genmab U.S.Meals · 2025-12-06Epkinly$122
AbbvieMeals · 2025-12-05Epkinly$149
Genmab U.S.Meals · 2025-11-08Epkinly$41
Genmab U.S.Meals · 2025-11-08Epkinly$102
Genmab U.S.Consulting · 2025-11-08Epkinly$3,386
Kite PharmaMeals · 2025-10-16Yescarta$31
E.R. Squibb & Sons L.L.C.Meals · 2025-08-29None$48
E.R. Squibb & Sons L.L.C.Travel · 2025-08-29None$91
AbbvieMeals · 2025-08-27Epkinly$108
E.R. Squibb & Sons L.L.C.Consulting · 2025-08-18None$9,073
CelgeneMeals · 2025-08-06None$65
CelgeneMeals · 2025-08-06None$28
CelgeneMeals · 2025-08-06None$30
CelgeneMeals · 2025-08-06None$50
CelgeneTravel · 2025-08-06None$462
CelgeneTravel · 2025-08-05None$293
AbbvieConsulting · 2025-07-14Epkinly$300
GenentechMeals · 2025-06-20Columvi$102
IncyteConsulting · 2025-05-29None$2,055
E.R. Squibb & Sons L.L.C.Consulting · 2025-03-05None$2,388
AbbvieMeals · 2025-01-30Imbruvica$21
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)

2024: $15,973

Payments by company in 2024
E.R. Squibb & Sons L.L.C.None$5,730
2 payments
  • Consulting · 2024-10-21 · $2,865
  • Consulting · 2024-09-30 · $2,865
Genmab U.S.Epkinly$4,289
11 payments
  • Consulting for Epkinly · 2024-05-02 · $2,925
  • Meals for Epkinly · 2024-04-20 · $16
  • Meals for Epkinly · 2024-04-20 · $34
  • Meals for Epkinly · 2024-04-20 · $48
  • Meals for Epkinly · 2024-04-20 · $50
  • Meals for Epkinly · 2024-04-20 · $24
  • Travel for Epkinly · 2024-04-20 · $20
  • Travel for Epkinly · 2024-04-19 · $28
  • Meals for Epkinly · 2024-04-19 · $138
  • Travel for Epkinly · 2024-04-19 · $259
  • Travel for Epkinly · 2024-04-19 · $748
Kite PharmaYescarta$3,700
1 payment
  • Consulting for Yescarta · 2024-01-04 · $3,700
AbbvieImbruvica$2,255
5 payments
  • Meals for Epkinly · 2024-10-31 · $4
  • Meals for Imbruvica · 2024-10-04 · $20
  • Meals for Imbruvica · 2024-05-14 · $25
  • Meals for Imbruvica · 2024-02-08 · $6
  • Consulting · 2024-01-23 · $2,200

2023: $4,423

Payments by company in 2023
E.R. Squibb & Sons L.L.C.None$3,691
2 payments
  • Meals · 2023-06-12 · $1
  • Consulting · 2023-01-06 · $3,690
SeagenNone$322
2 payments
  • Meals · 2023-06-16 · $172
  • Meals · 2023-02-01 · $150
Genmab U.S.Epkinly$137
1 payment
  • Meals for Epkinly · 2023-12-09 · $137
AbbVieEpkinly$130
3 payments
  • Meals for Epkinly · 2023-11-11 · $60
  • Meals for Epkinly · 2023-11-11 · $20
  • Meals for Epkinly · 2023-11-11 · $50
AstraZeneca Pharmaceuticals LPCalquence$65
1 payment
  • Meals for Calquence · 2023-12-08 · $65
Pharmacyclics LLC An AbbVieImbruvica$47
2 payments
  • Meals for Imbruvica · 2023-10-25 · $17
  • Meals for Imbruvica · 2023-05-18 · $30
Genentech USALunsumio$32
1 payment
  • Meals for Lunsumio · 2023-02-07 · $32

2022: $11,521

Payments by company in 2022
Kite PharmaTecartus$5,000
1 payment
  • Consulting for Tecartus · 2022-04-22 · $5,000
E.R. Squibb & Sons L.L.C.None$2,212
2 payments
  • Travel · 2022-06-30 · $60
  • Consulting · 2022-06-16 · $2,153
AstraZeneca Pharmaceuticals LPCalquence$1,980
2 payments
  • Consulting for Calquence · 2022-06-26 · $1,884
  • Meals for Calquence · 2022-06-03 · $97
Pharmacyclics LLC an AbbVieImbruvica$1,650
2 payments
  • Consulting for Imbruvica · 2022-11-17 · $1,100
  • Consulting for Imbruvica · 2022-11-10 · $550
SeagenNone$409
4 payments
  • Meals · 2022-12-10 · $73
  • Meals · 2022-08-18 · $99
  • Meals · 2022-07-11 · $94
  • Meals · 2022-05-25 · $142
CelgeneNone$222
4 payments
  • Meals · 2022-12-13 · $38
  • Meals · 2022-12-10 · $29
  • Meals · 2022-06-06 · $30
  • Meals · 2022-06-06 · $125
AbbvieVenclexta$48
1 payment
  • Meals for Venclexta · 2022-10-13 · $48

2021: $4,523

Payments by company in 2021
Kite PharmaTecartus$2,250
1 payment
  • Consulting for Tecartus · 2021-12-03 · $2,250
EpizymeTazverik$2,175
1 payment
  • Honoraria for Tazverik · 2021-01-01 · $2,175
Acrotech BiopharmaBeleodaq$40
3 payments
  • Education for Beleodaq · 2021-12-01 · $14
  • Education for Beleodaq · 2021-10-05 · $12
  • Education for Beleodaq · 2021-10-05 · $14
CelgeneNone$31
1 payment
  • Meals · 2021-12-10 · $31
Pharmacyclics LLC An AbbVieImbruvica$27
1 payment
  • Meals for Imbruvica · 2021-05-19 · $27

2020: $10,695

Payments by company in 2020
IncyteNone$7,995
2 payments
  • Consulting · 2020-07-14 · $3,075
  • Consulting · 2020-06-06 · $4,920
Kite PharmaYescarta$2,700
1 payment
  • Consulting for Yescarta · 2020-09-11 · $2,700

2019: $19,640

Payments by company in 2019
Gilead SciencesNone$12,781
8 payments
  • Consulting · 2019-11-06 · $7,530
  • Travel · 2019-09-08 · $495
  • Meals · 2019-09-07 · $136
  • Travel · 2019-09-07 · $48
  • Travel · 2019-09-05 · $55
  • Travel · 2019-09-04 · $2,877
  • Consulting · 2019-08-01 · $1,610
  • Travel · 2019-08-01 · $30
Jazz PharmaceuticalsNone$5,663
9 payments
  • Consulting · 2019-05-07 · $450
  • Consulting · 2019-03-19 · $4,050
  • Meals · 2019-03-02 · $38
  • Travel · 2019-03-02 · $70
  • Travel · 2019-03-02 · $29
  • Travel · 2019-03-02 · $528
  • Travel · 2019-03-02 · $125
  • Travel · 2019-03-02 · $259
  • Meals · 2019-03-02 · $114
Novartis PharmaceuticalsKymriah$1,136
10 payments
  • Meals for Kymriah · 2019-12-08 · $0
  • Meals for Kymriah · 2019-12-07 · $10
  • Meals for Kymriah · 2019-10-18 · $135
  • Travel · 2019-10-17 · $356
  • Travel for Kymriah · 2019-10-17 · $207
  • Travel for Kymriah · 2019-10-17 · $172
  • Meals for Kymriah · 2019-10-17 · $75
  • Meals for Kymriah · 2019-10-17 · $125
  • Meals for Kymriah · 2019-06-19 · $32
  • Meals for Kymriah · 2019-04-24 · $23
Kite PharmaNone$60
1 payment
  • Meals · 2019-12-07 · $60

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
Celgene Corporation · A Study To Compare the Efficacy and Safety of Jcar017 To Standard of Care in Adult Subjects With High-Risk, Transplant-Eligible Relapsed Or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (Transform) (Jcar017-Bcm-003) · 2019Their institution$494,050
Genmab U.S., Inc. · A Phase 1/2, Open-Label Safety Trial of Gen3013 in Patients With Relapsed, Progressive Or Refractory B-Cell Lymphoma. · 2023Their institution$344,158
Merck Sharp & Dohme Corporation · A Phase 1,Phase 2 Clinical Study To Evaluate the Safety and Efficacy of A Combination of Mk-4280 and Pembrolizumab Mk-3475 in Participants With Hematologic Malignancies · 2021Their institution$322,940
Genmab U.S., Inc. · A Phase 1/2, Open-Label Safety Trial of Gen3013 in Patients With Relapsed, Progressive Or Refractory B-Cell Lymphoma. · 2024Their institution$314,001
Hoffmann-La Roche Limited · Phase 1b Study of Each Glofitammab and Mosunetuzumab in Combination With M Cc20 and M Cc82 in Nhl · 2025Their institution$283,683
Celgene Corporation · A Study To Compare the Efficacy and Safety of Jcar017 To Standard of Care in Adult Subjects With High-Risk, Transplant-Eligible Relapsed Or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (Transform) · 2022Their institution$263,497
Celgene Corporation · Expanded Access Protocol (Eap) of Patients Receiving Nonconforming Lisocabtagene Maraleucel That Is Out of Specification (Oos) for Commercial Release (Jcar017-Nhl-001) · 2019Their institution$227,178
Celgene Corporation · Study Evaluating the Safety and Pharmacokinetics of Jcar017 in B-Cell Non-Hodgkin Lymphoma (Transcend-Nhl-001) (17001) · 2019Their institution$209,001
Celgene Corporation · A Study To Compare the Efficacy and Safety of Jcar017 To Standard of Care in Adult Subjects With High-Risk, Transplant-Eligible Relapsed Or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (Transform) · 2020Their institution$196,709
Novartis Pharmaceuticals Corporation · A Phase II Single Arm Multicenter Open Label Trial To Determine the Efficacy and Safety of Ctl019 in Adult Patients With Refractory Or Relapsed Follicular Lymphoma · 2020Their institution$196,253
Merck Sharp & Dohme Corporation · A Phase 1,Phase 2 Clinical Study To Evaluate the Safety and Efficacy of A Combination of Mk-4280 and Pembrolizumab Mk-3475 in Participants With Hematologic Malignancies · 2020Their institution$188,469
Genentech, Inc. · Phase 1 Eih Cd19 4 1bbl · 2025Their institution$171,618
E.R. Squibb & Sons, L.L.C. · Study Evaluating the Safety and Pharmacokinetics of Jcar017 in B-Cell Non-Hodgkin Lymphoma (Nhl) · 2024Their institution$162,391
Genentech, Inc. · Phase 1 Eih Cd19 4 1bbl · 2023Their institution$158,247
Hoffmann-La Roche Limited · Phase 1b Study of Each Glofitammab and Mosunetuzumab in Combination With M Cc20 and M Cc82 in Nhl · 2024Their institution$155,075
Novartis Pharmaceuticals Corporation · Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed Or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial (Belinda) · 2020Their institution$152,563
Lilly USA, LLC · A Multicenter Phase 2 Study of Glofitamab With Pirtobrutinib for Relapsed Or Refractory Mantle Cell Lymphoma · 2024Their institution$144,214
Genentech, Inc. · Glofit Pirto in Nhl · 2025Their institution$121,682
Celgene Corporation · Study Evaluating the Safety and Pharmacokinetics of Jcar017 in B-Cell Non-Hodgkin Lymphoma (Transcend-Nhl-001) · 2020Their institution$120,277
Genmab A/S · A Phase 1b/2, Open-Label Trial To Assess the Safety and Preliminary Efficacy of Epcoritamab (Gen3013; Duobody-Cd3xcd20) in Combination With Other Agents in Subjects With B-Cell Non-Hodgkin Lymphoma. · 2025Their institution$119,074
Novartis Pharmaceuticals Corporation · A Phase II Single Arm Multicenter Open Label Trial To Determine the Efficacy and Safety of Ctl019 in Adult Patients With Refractory Or Relapsed Follicular Lymphoma · 2023Their institution$111,334
Hoffmann-La Roche Limited · Phase 1b Study of Each Glofitammab and Mosunetuzumab in Combination With M Cc20 and M Cc82 in Nhl · 2023Their institution$103,357
Pharmacyclics LLC, an AbbVie Company · A Randomized Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma of the Activated-B-Cell Subtype · 2022Their institution$100,000
Pharmacyclics LLC, An AbbVie Company · Imbruvica · 2020Their institution$100,000
Pharmacyclics LLC, an AbbVie Company · A051301: A Randomized Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma of the Activated-B-Cell Subtype · 2021Their institution$100,000
Pharmacyclics LLC, an AbbVie Company · A Randomized Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma of the Activated-B-Cell Subtype · 2023Their institution$100,000
Merck Sharp & Dohme LLC · A Phase 1,Phase 2 Clinical Study To Evaluate the Safety and Efficacy of A Combination of Mk-4280 and Pembrolizumab Mk-3475 in Participants With Hematologic Malignancies · 2022Their institution$89,013
Novartis Pharmaceuticals Corporation · Phase II Diffuse Large B Cell Lymphoma Dlbcl · 2019Their institution$88,087
Celgene Corporation · A Phase I, Open-Label, Dose Finding Study of Cc-90002, A Monoclonal Antibody Directed Against Cd47, in Subjects With Advanced Solid and Hematologic Cancers · 2020Their institution$79,164
Amgen Inc. · [Nccn] A Phase Ib Dose Escalation Trial of Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed Or Refractory Non-Hodgkin Lymphoma · 2019Their institution$74,285
Celgene Corporation · Study Evaluating the Safety and Pharmacokinetics of Jcar017 in B-Cell Non-Hodgkin Lymphoma (Transcend-Nhl-001) · 2022Their institution$72,072
Genmab A/S · A Phase 1b/2, Open-Label Trial To Assess the Safety and Preliminary Efficacy of Epcoritamab (Gen3013; Duobody-Cd3xcd20) in Combination With Other Agents in Subjects With B-Cell Non-Hodgkin Lymphoma. · 2023Their institution$71,550
Novartis Pharmaceuticals Corporation · Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed Or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial (Belinda) · 2021Their institution$71,458
Novartis Pharmaceuticals Corporation · A Phase II Single Arm Multicenter Open Label Trial To Determine the Efficacy and Safety of Ctl019 in Adult Patients With Refractory Or Relapsed Follicular Lymphoma · 2019Their institution$70,804
Celgene Corporation · A Phase I, Open-Label, Dose Finding Study of Cc-90002, A Monoclonal Antibody Directed Against Cd47, in Subjects With Advanced Solid and Hematologic Cancers · 2021Their institution$56,008
Merck Sharp & Dohme Corporation · A Phase 1,Phase 2 Clinical Study To Evaluate the Safety and Efficacy of A Combination of Mk-4280 and Pembrolizumab Mk-3475 in Participants With Hematologic Malignancies · 2019Their institution$55,088
Celgene Corporation · A Global Randomized Multicenter Phase 3 Trial of J · 2021Their institution$52,391
Celgene Corporation · Transcend 3l+ Cll- 17004 (Ph 1/2) - An Open-Label, Phase 1/2 Study of Jcar017 in Subjects With Relapsed Or Refractory Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma (017004) · 2023Their institution$46,769
Genmab A/S · A Phase 1b/2, Open-Label Trial To Assess the Safety and Preliminary Efficacy of Epcoritamab (Gen3013; Duobody-Cd3xcd20) in Combination With Other Agents in Subjects With B-Cell Non-Hodgkin Lymphoma. · 2024Their institution$44,800
Celgene Corporation · Long-Term Follow-Up Protocol for Participants Treated With Gene-Modified T Cells. A Prospective Study for the Long-Term Follow-Up (Ltfu) of Safety and Efficacy for All Pediatric and Adult Participants Exposed To Gene-Modified (Gm) T-Cell Therapy Participating in A Previous Celgene Sponsored Or Celgene Alliance Partner Sponsored Study. · 2025Their institution$43,177
Novartis Pharmaceuticals Corporation · Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed Or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial (Belinda) · 2022Their institution$42,208
Genentech, Inc. · Phase 1 Eih Cd19 4 1bbl · 2024Their institution$40,584
Celgene Corporation · Transcend 3l+ Cll- 17004 (Ph 1/2) - An Open-Label, Phase 1/2 Study of Jcar017 in Subjects With Relapsed Or Refractory Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma (017004) · 2024Their institution$36,421
Novartis Pharmaceuticals Corporation · Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed Or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial (Belinda) · 2019Their institution$32,674
E.R. Squibb & Sons, L.L.C. · Study Evaluating the Safety and Pharmacokinetics of Jcar017 in B-Cell Non-Hodgkin Lymphoma (Nhl) · 2025Their institution$31,516
Novartis Pharmaceuticals Corporation · Phase II Diffuse Large B Cell Lymphoma Dlbcl · 2023Their institution$30,839
Celgene Corporation · Long-Term Follow-Up Protocol for Participants Treated With Gene-Modified T Cells · 2023Their institution$29,899
Celgene Corporation · Long-Term Follow-Up Protocol for Participants Treated With Gene-Modified T Cells · 2024Their institution$29,407
Celgene Corporation · Transform 2l Te Lbcl Bcm-003 - A Global Randomized Multicenter Phase 3 Trial of Jcar017 Compared To Standard of Care in Adult Subjects With High-Risk, Second-Line, Transplant-Eligible Relapsed Or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (Transfo · 2023Their institution$29,063
Celgene Corporation · (Jcar017-Eap-001) Expanded Access (Out of Spec) - Expanded Access Protocol (Eap) of Subjects Receiving Nonconforming Lisocabtagene Maraleucel That Is Out of Specification (Oos) for Commercial Release · 2023Their institution$28,826
Novartis Pharmaceuticals Corporation · A Phase II Single Arm Multicenter Open Label Trial To Determine the Efficacy and Safety of Ctl019 in Adult Patients With Refractory Or Relapsed Follicular Lymphoma · 2022Their institution$28,301
Novartis Pharmaceuticals Corporation · Phase II Diffuse Large B Cell Lymphoma Dlbcl · 2021Their institution$27,885
Novartis Pharmaceuticals Corporation · Phase II Diffuse Large B Cell Lymphoma Dlbcl · 2022Their institution$25,576
Novartis Pharmaceuticals Corporation · A Phase II Single Arm Multicenter Open Label Trial To Determine the Efficacy and Safety of Ctl019 in Adult Patients With Refractory Or Relapsed Follicular Lymphoma · 2024Their institution$24,434
Celgene Corporation · Long-Term Follow-Up Protocol for Subjects Treated · 2022Their institution$24,387
Genmab U.S., Inc. · A Phase 1/2, Open-Label Safety Trial of Gen3013 in Patients With Relapsed, Progressive Or Refractory B-Cell Lymphoma. · 2025Their institution$24,128
Celgene Corporation · Study Evaluating the Safety and Pharmacokinetics of Jcar017 in B-Cell Non-Hodgkin Lymphoma (Nhl) · 2025Their institution$22,877
Novartis Pharmaceuticals Corporation · Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed Or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial (Belinda) · 2023Their institution$20,179
Novartis Pharmaceuticals Corporation · A Phase II Study of Intensive Consolidation and Stem Cell Mobilization Therapy With Ofatumumab Etoposide and High Dose Arac Ova Followed By Autologous Stem Cell Transplantation in High Risk Patients With Relapsed and Or Refractory Diffuse Large Bcell Lymp · 2019Their institution$18,976
Celgene Corporation · A Study To Compare the Efficacy and Safety Ofjcar017to Standard of Care in Adult Subjects With High-Risk, Transplant-Eligible Relapsed Or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (Transform) · 2024Their institution$18,218
Novartis Pharmaceuticals Corporation · Long Term Follow Up of Patients Exposed To Lentiviral Based Cd19 Directed Car T Cell Therapy · 2024Their institution$15,361
Celgene Corporation · Study Evaluating the Safety and Pharmacokinetics of Jcar017 in B-Cell Non-Hodgkin Lymphoma (Transcend-Nhl-001) · 2023Their institution$13,797
Novartis Pharmaceuticals Corporation · Long Term Follow Up of Patients Exposed To Lentiviral Based Cd19 Directed Car T Cell Therapy · 2023Their institution$10,989
Novartis Pharmaceuticals Corporation · Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed Or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial (Belinda) · 2024Their institution$10,305
Novartis Pharmaceuticals Corporation · A Phase II Single Arm Multicenter Open Label Trial To Determine the Efficacy and Safety of Ctl019 in Adult Patients With Refractory Or Relapsed Follicular Lymphoma · 2021Their institution$9,371
Celgene Corporation · Expanded Access Protocol (Eap) for Subjects Receiving Lisocabtagene Maraleucel That Is Nonconforming for Commercial Release · 2024Their institution$9,231
Celgene Corporation · Study Evaluating the Safety and Pharmacokinetics of Jcar017 in B-Cell Non-Hodgkin Lymphoma (Transcend-Nhl-001) · 2024Their institution$9,198
Novartis Pharmaceuticals Corporation · Long Term Follow Up of Patients Exposed To Lentiviral Based Cd19 Directed Car T Cell Therapy · 2021Their institution$8,512
Celgene Corporation · (Jcar017-Eap-001) Expanded Access (Out of Spec) (Bms Study Number: Ca082-P27) - Expanded Access Protocol (Eap) of Subjects Receiving Nonconforming Lisocabtagene Maraleucel That Is Out of Specification (Oos) for Commercial Release · 2022Their institution$5,171
Novartis Pharmaceuticals Corporation · Long Term Follow Up of Patients Exposed To Lentiviral Based Cd19 Directed Car T Cell Therapy · 2019Their institution$4,256
Novartis Pharmaceuticals Corporation · Long Term Follow Up of Patients Exposed To Lentiviral Based Cd19 Directed Car T Cell Therapy · 2020Their institution$4,256
Novartis Pharmaceuticals Corporation · Phase II Diffuse Large B Cell Lymphoma Dlbcl · 2020Their institution$2,453
Celgene Corporation · Expanded Access Protocol (Eap) of Subjects Receiving Nonconforming Lisocabtagene Maraleucel That Is Out of Specification (Oos) for Commercial Release · 2025Their institution$2,110
Novartis Pharmaceuticals Corporation · Long Term Follow Up of Patients Exposed To Lentiviral Based Cd19 Directed Car T Cell Therapy · 2025Their institution$1,851
Celgene Corporation · (Jcar017-Eap-001) Expanded Access (Out of Spec) (Bms Study Number: Ca082-P27) · 2021Their institution$1,500
Karyopharm Therapeutics Inc. · A Phase 2b Open-Label Study of Selinexor (Kpt 330) in Patients With Relapsed Refractory Diffuse Large B-Cell Lymphoma (Dlbcl) · 2022Their institution$1,475
Celgene Corporation · A Study Related To Non-Hodgkin Lymphoma, Compares the Efficacy of Obinutizumab in Combination With Chemotherapy Versus Rituximab- Based Treatments for Untreated Advanced Cases (Cl-Nhl-13648) · 2019This clinician$1,411
Celgene Corporation · Study Evaluating the Safety and Pharmacokinetics of Jcar017 in B-Cell Non-Hodgkin Lymphoma (Transcend-Nhl-001) · 2021Their institution$1,145
Celgene Corporation · An Open-Label, Phase 1/2 Study of Jcar017 in Subjects With Relapsed Or Refractory Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma (017004) (17004) · 2019This clinician$1,144
F. Hoffmann-La Roche AG · Phase 1b Study of Each Glofitammab and Mosunetuzumab in Combination With M Cc20 and M Cc82 in Nhl · 2025This clinician$1,038
E.R. Squibb & Sons, L.L.C. · An Open-Label, Phase 1/2 Study of Jcar017 in Subjects With Relapsed Or Refractory Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma (017004) · 2025Their institution$937
Novartis Pharmaceuticals Corporation · A Phase II Single Arm Multicenter Open Label Trial To Determine the Efficacy and Safety of Ctl019 in Adult Patients With Refractory Or Relapsed Follicular Lymphoma · 2025Their institution$757
Novartis Pharmaceuticals Corporation · Cctl019e2202 · 2023This clinician$638
Celgene Corporation · A Phase I, Open-Label, Dose Finding Study of Cc-90002, A Monoclonal Antibody Directed Against Cd47, in Subjects With Advanced Solid and Hematologic Cancers (Cc-90002-St-001) · 2019This clinician$476
Novartis Pharmaceuticals Corporation · A Phase II Single Arm Multicenter Open Label Trial To Determine the Efficacy and Safety of Ctl019 in Adult Patients With Refractory Or Relapsed Follicular Lymphoma · 2021This clinician$355
Novartis Pharmaceuticals Corporation · Cctl019e2202 · 2024This clinician$349
E.R. Squibb & Sons, L.L.C. · Expanded Access Protocol (Eap) of Subjects Receiving Nonconforming Lisocabtagene Maraleucel That Is Out of Specification (Oos) for Commercial Release · 2025Their institution$267
NOVARTIS PHARMACEUTICALS CORPORATION · Research Related Publications Support · 2019This clinician$224
Merck Sharp & Dohme LLC · A Phase 1,Phase 2 Clinical Study To Evaluate the Safety and Efficacy of A Combination of Mk-4280 and Pembrolizumab Mk-3475 in Participants With Hematologic Malignancies · 2023Their institution$223
Novartis Pharmaceuticals Corporation · Research Publication/ Writing Support · 2025This clinician$115

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
75.0 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1205877669
Licence
PA MD073649L
Trained
Columbia University College of Physicians and Surgeons, 1998 · 28 years ago
Group
University of California San Francisco · UCSF Medical Group Business Services · Regents of the University of California
Video visits
Lists video visits
Gender
Male
More record details
Sole proprietor
No
Medicaid ID
PA 1010419220001
Taxonomy
Medical oncology (207RX0202X)
Mailing address
3400 Spruce St, 15 Penn Tower, Philadelphia, PA, 19104
NPI first listed
2006-06-09
NPI last updated
2011-01-21

This is when the NPI record was last certified, not a medical board exam.